CHMP OKs First EU Biosimilar Herceptin, And Another Version Of Humira

 
• By Ian Schofield

Samsung Bioepis’s Ontruzant is set to be the first biosimilar version of Roche’s Herceptin on the EU market after getting the all-clear from the EMA’s CHMP on Sept. 15. The committee has also OKd another version of AbbVie’s Humira, this time from Boehringer Ingelheim.

Recommendation
The first biosimilar Herceptin has been recommended for approval in the EU.

More from Approvals

More from Product Reviews